Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Drug Proves Helpful for Treating Long-Term Insomnia

22.10.2003


Researchers at Duke University Medical Center and elsewhere have completed the first large-scale study demonstrating sustained efficacy of a medication to treat insomnia for a period of six months.



Eszopiclone (trade name Estorra), was administered nightly to patients with chronic insomnia and led to significant improvement in patients’ ability to fall asleep and stay asleep and in the quality of their sleep without any evidence of a loss of effect over time, the researchers said. Prior to this study, the longest large-scale, placebo-controlled study of a sleep medication for insomnia lasted five weeks.

The data further demonstrate that improvements in sleep were associated with consistent improvements in the patients’ ratings of their capacity to function well during the day, said the researchers. Impairments in daytime function are one aspect of chronic insomnia, and the new study represents the first time any sleep medication has been shown to consistently improve all of the components that define insomnia, they said.


Insomnia is the perception of inadequate or poor-quality sleep that is accompanied by significant distress or impaired function. It is considered to be chronic if it occurs on most nights and lasts a month or more, according to the National Institute of Health.

"I believe that this study is a milestone for research into insomnia treatments," said Andrew Krystal, M.D., lead study author and associate professor of psychiatry and director of the Sleep Research Laboratory and Insomnia Clinic at Duke. "It greatly extends the period of time that a medication has been definitively shown to help people suffering from insomnia and it establishes that studies of longer-term drug treatment of insomnia are not only feasible but can be safely performed."

The research findings appear in the Nov. 1, 2003, issue of the journal Sleep.

The researchers randomized 788 patients aged 21 to 69 into a six-month, double-blind, placebo-controlled study of three-milligram nightly doses of eszopiclone to treat their insomnia. Participants were required to meet the standard criteria used to make the clinical diagnosis of primary insomnia and to report, on average, less than six-and-a-half hours of sleep per night, or that it took at least 30 minutes to fall asleep for at least one month prior to being screened for the study.

According to Krystal, the results provide the first step toward establishing an empirical base to guide the long-term treatment of chronic insomnia with medication. The findings suggest that eszopiclone has the potential to provide doctors with a treatment option that could be prescribed for patients who require longer-term treatment. The data demonstrate that eszopiclone is safe and could be helpful. By opening the door for future studies of longer-term treatments for insomnia, this study represents an important step in the evolution toward improving treatment options for patients with chronic insomnia, he added.

"The fact that eszopiclone improved not only the difficulties in sleep that patients experience but also their reports of problems they typically experience during their waking hours, suggests the need for a change in our perspective," Krystal said. "The idea that effective treatment should address the entire spectrum of difficulties experienced by patients with insomnia is really a new way of thinking for the field."

An estimated 2.5 percent of Americans take sleep medications for insomnia in any given year, the researchers report. Of these, about 23 percent take such medications on a nightly basis for four months or longer. However, clinical research studies have examined the use of such drugs for an average use of one week. The problem with this, the researchers say, is that long-term drug treatment is being carried out without the existence of research supporting that long-term use is safe or effective in adults.

Nearly 60 percent of American adults surveyed about their sleep habits say they experience sleep problems more than a few times each week, according to the National Sleep Foundation. In their 2003 "Sleep in America" poll, the group found that insomnia is the most common sleep problem and that only one in eight older adults say their problems have been diagnosed.

Of the many people who report sleep problems, 20 to 36 percent report that their problem lasted for more than one year. Thus, the researchers say, it is not surprising that so many people are using sleep medications for long periods of time.

Research funding was supported by Sepracor, Inc., the manufacturer of eszopiclone, a compound currently under review by the Food and Drug Administration.

Krystal has previously designed and conducted other studies for Sepracor and has served on an advisory board there.

Other authors on the study include James Walsh, Ph.D., of St. John’s/St. Luke’s Hospital and St. Louis University; Eugene Laska, Ph.D., of Nathan Klein Institute for Psychiatric Research and New York University School of Medicine; Judy Caron, Ph.D., of Sepracor, Inc. in Marlborough, Mass.; and David Amato, Ph.D., Thomas Wessel, Ph.D., and Thomas Roth, Ph.D., all of Henry Ford Sleep Disorders Center in Detroit, Mich.

Tracey Koepke | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7126

More articles from Health and Medicine:

nachricht Building blocks for new medications: the University of Graz is seeking a technology partner
19.03.2019 | Karl-Franzens-Universität Graz

nachricht Scientists find new approach that shows promise for treating cystic fibrosis
14.03.2019 | NIH/National Heart, Lung and Blood Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Stellar cartography

The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.

A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...

Im Focus: Heading towards a tsunami of light

Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have proposed a way to create a completely new source of radiation. Ultra-intense light pulses consist of the motion of a single wave and can be described as a tsunami of light. The strong wave can be used to study interactions between matter and light in a unique way. Their research is now published in the scientific journal Physical Review Letters.

"This source of radiation lets us look at reality through a new angle - it is like twisting a mirror and discovering something completely different," says...

Im Focus: Revealing the secret of the vacuum for the first time

New research group at the University of Jena combines theory and experiment to demonstrate for the first time certain physical processes in a quantum vacuum

For most people, a vacuum is an empty space. Quantum physics, on the other hand, assumes that even in this lowest-energy state, particles and antiparticles...

Im Focus: Sussex scientists one step closer to a clock that could replace GPS and Galileo

Physicists in the EPic Lab at University of Sussex make crucial development in global race to develop a portable atomic clock

Scientists in the Emergent Photonics Lab (EPic Lab) at the University of Sussex have made a breakthrough to a crucial element of an atomic clock - devices...

Im Focus: Sensing shakes

A new way to sense earthquakes could help improve early warning systems

Every year earthquakes worldwide claim hundreds or even thousands of lives. Forewarning allows people to head for safety and a matter of seconds could spell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International Modelica Conference with 330 visitors from 21 countries at OTH Regensburg

11.03.2019 | Event News

Selection Completed: 580 Young Scientists from 88 Countries at the Lindau Nobel Laureate Meeting

01.03.2019 | Event News

LightMAT 2019 – 3rd International Conference on Light Materials – Science and Technology

28.02.2019 | Event News

 
Latest News

Levitating objects with light

19.03.2019 | Physics and Astronomy

New technique for in-cell distance determination

19.03.2019 | Life Sciences

Stellar cartography

19.03.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>